The Boston Globe takes a look at Knome, the consumer genomic company that sequences its customers' genomes while rounding up the challenges facing the field -- those cease-and-desist letters and the debate over medical relevance. The writer, Scott Kirsner, asks Raju Kucherlapati and David Altshuler if they'd get their genomes sequenced.